Skip to content

Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.

Contemp Clin Trials March 2, 2026 Peer reviewed DOI: 10.1016/j.cct.2026.108273 via PubMed

Summary

The EQUIVALENCE trial protocol outlines a study comparing the effectiveness of intravenous ketamine to intranasal esketamine in treating patients with treatment-resistant depression. The goal is to determine if intravenous ketamine is non-inferior to intranasal esketamine in terms of efficacy for this patient group.

Study at a glance

Design comparative effectiveness study
Population patients with treatment-resistant depression

Abstract

Non-inferiority, comparative effectiveness study of intravenous ketamine v. intranasal esketamine for treatment-resistant depression: The EQUIVALENCE trial protocol.

Comments

No comments yet.

Log in to comment